385 related articles for article (PubMed ID: 35523436)
1. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
2. Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
Su X; Jin K; Guo Q; Xu Z; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
Br J Cancer; 2024 Mar; 130(5):852-860. PubMed ID: 38212482
[TBL] [Abstract][Full Text] [Related]
3. POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Liu H; Zhang W
Cancer Med; 2024 Feb; 13(4):e6962. PubMed ID: 38457207
[TBL] [Abstract][Full Text] [Related]
4. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
[TBL] [Abstract][Full Text] [Related]
5. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
6. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
[TBL] [Abstract][Full Text] [Related]
7. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
[TBL] [Abstract][Full Text] [Related]
8. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
9. Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients.
Liu C; Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Zhu Y; Zhang W
Br J Cancer; 2022 Nov; 127(9):1718-1725. PubMed ID: 35999267
[TBL] [Abstract][Full Text] [Related]
10. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
11. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
Fan B; Zheng X; Wang Y; Hu X
Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269
[No Abstract] [Full Text] [Related]
12. Integration of CD4
Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Liu H; Chang Y; Zhu Y; Xu L; Wang Z; Wang Y; Zhang W
Cancer Sci; 2024 Apr; 115(4):1306-1316. PubMed ID: 38402640
[TBL] [Abstract][Full Text] [Related]
13. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
[TBL] [Abstract][Full Text] [Related]
14. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
15. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
16. Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients.
Ma J; Zhou Q; Xu W; Li C; Wang H; Zhai Z; Zhang Y; Wahafu W
Int Immunopharmacol; 2023 Jan; 114():109535. PubMed ID: 36527880
[TBL] [Abstract][Full Text] [Related]
17. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
19. Dynamic alteration and prognostic significance of tumor-associated CD68
Wu J; Xie RY; Wei LH; Cao CZ; Shang BQ; Guan YY; Shi HZ; Qu W; Li Y; Liang J; Zheng S; Zhou AP; Zhou XF; Shou JZ; Bi XG
Cancer Med; 2023 Feb; 12(4):4981-4992. PubMed ID: 36043478
[TBL] [Abstract][Full Text] [Related]
20. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]